| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Zymeworks Inc. | Chief Scientific Officer | Common Shares | 36,407 | $164,196 | $4.51 | 07 Jan 2022 | Direct |
| BRAINSTORM CELL THERAPEUTICS INC. | Director | Common Stock | 25,730 | $5,866 | $0.2280 | 01 Jan 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | 01 Jan 2025 | 1 | $0 | 4 | Director | 03 Jan 2025, 17:34 |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | 01 Feb 2022 | 1 | $0 | 4 | Director | 03 Feb 2022, 15:33 |
| /report/000089924322001424-polverino-anthony-j-2022-01-07 | Zymeworks Inc. | 07 Jan 2022 | 1 | +$1,032 | 4 | Chief Scientific Officer | 07 Jan 2022, 20:30 |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | 15 Dec 2021 | 1 | $0 | 4 | Director | 17 Dec 2021, 16:03 |
| BCLI | BRAINSTORM CELL THERAPEUTICS INC. | 10 Dec 2021 | 2 | $0 | 4 | Director | 10 Dec 2021, 19:03 |
| /report/000089924321034985-polverino-anthony-j-2021-08-31 | Zymeworks Inc. | 31 Aug 2021 | 2 | +$73,500 | 4 | Chief Scientific Officer | 02 Sep 2021, 20:00 |
| /report/000089924321027914-polverino-anthony-j-2021-07-06 | Zymeworks Inc. | 06 Jul 2021 | 1 | +$13,388 | 4 | Chief Scientific Officer | 08 Jul 2021, 20:00 |